Not Yet Recruiting A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway NCT06614751 Conditions Advanced Cancer, BRCA Mutation, Breast Cancer, +44 more Locations Peking University Cancer Hospital and Institute — Beijing, Beijing Municipality, China Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijjing, Beijing Municipality, China View Trial Details
Completed A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors NCT04826341 Conditions Advanced Solid Tumors, HRD Cancer, SCLC Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
